secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0000950170-24-025867
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix Q4 net sales $200.4M (+7% pro forma constant currency); FY24 guidance implies 5-7% growth
--------------------------------------------------------------------------------

- Q4 net sales $200.4M; Bone Growth Therapies up 15% YoY; U.S. spine fixation up 13.5%.
- Q4 net loss $(22.2)M ($(0.59)/share); Non-GAAP adjusted EBITDA $19.6M (9.8% of sales), up 96% YoY pro forma.
- Full-year 2023 net sales $746.6M; net loss $(151.4)M; adjusted EBITDA $46.3M (6.2% of sales), up 69%.
- FY24 guidance: net sales $785M-$795M (5-7% constant currency growth); adjusted EBITDA $62M-$67M; exit Q4 FCF positive.
- Achieved $32M in annualized merger-related synergies; cash $37.8M, $100M drawn on $150M credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/0000950170-24-025867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/ofix-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-025867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer